Kentucky Attorney General Andy Beshear claims the three major insulin manufacturers violated the state’s consumer protection law when they raised the price of insulin at the expense of taxpayers. The three insulin companies control 96 percent of the insulin market, Mr. Beshear said.
Eli Lilly, Sanofi and Novo Nordisk have raised the price of insulin products to an average of $300, although production costs are less than $7 per vial, the lawsuit alleges.
“It is truly heartbreaking that Kentuckians are suffering, sometimes risking life and limb, because they cannot afford their medications,” Mr. Beshear told The Hill. “The outrageous actions of these drug companies is a big reason we all pay too much for prescription drugs, and I am insisting they pay up for putting profits ahead of our Kentucky families.”
More articles on pharmacy:
8 recent pharmaceutical lawsuits, settlements
McKesson renews distribution deal with CVS Health
Sacklers discussed selling Purdue Pharma in 2000, court documents reveal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
